Phaseline

Targets › 5-FU

5-FU: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: the race on 5-FU, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoFlucytosine (DB107)
Thymidylate synthase inhibitor
5-FUPhase 1High Grade GliomaJan 2028

Conditions

High Grade Glioma (1)

Modalities

mixed (1)

Companies

University of California, San Francisco (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.